Nuvectis Pharma, Inc.
NASDAQ:NVCT
6.7 (USD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | -4.101 | 0 | 0 | 4.101 | 0.149 | 0 | 0 | 0 | 0.004 | 0 | 0 | 0 |
| Cost of Revenue
| 4.643 | 4.396 | 10.967 | 6.158 | 5.772 | 0 | 0 | 5.938 | 3.573 | 2.945 | 0 | 0 | 0 | 0 |
| Gross Profit
| -4.643 | -4.396 | -15.068 | -6.158 | -5.772 | 4.101 | 0.149 | -5.938 | -3.573 | -2.945 | 0.004 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 3.674 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 2.943 | 2.66 | 4.265 | 4.486 | 4.262 | 2.367 | 4.397 | 4.52 | 2.505 | 1.805 | 1.144 | 4.156 | 4.245 | 0 |
| General & Administrative Expenses
| 1.7 | 1.736 | 2.601 | 1.672 | 1.51 | 1.734 | 2.381 | 1.418 | 1.068 | 1.14 | 1.121 | 0.512 | 1.693 | 0.023 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 1.7 | 1.736 | 2.601 | 1.672 | 1.51 | 1.734 | 2.381 | 1.418 | 1.068 | 1.14 | 1.121 | 0.512 | 1.693 | 0.023 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 4.643 | 4.396 | 6.866 | 6.158 | 5.772 | 4.101 | 6.778 | 5.938 | 3.573 | 2.945 | 2.265 | 4.668 | 5.938 | 0.023 |
| Operating Income
| -4.643 | -4.396 | -6.866 | -6.158 | -5.772 | -4.101 | -6.778 | -5.938 | -3.573 | -2.941 | -2.265 | -4.668 | -5.938 | -0.023 |
| Operating Income Ratio
| 0 | 0 | 1.674 | 0 | 0 | -1 | -45.49 | 0 | 0 | 0 | -566.25 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.215 | 0.225 | 0.244 | 6.435 | 5.836 | 0.052 | 0.082 | 0.061 | 0.004 | -0.002 | 0.004 | 0 | 0 | 0 |
| Income Before Tax
| -4.428 | -4.171 | -6.622 | -5.881 | -5.708 | -4.049 | -6.696 | -5.877 | -3.569 | -2.943 | -2.261 | -4.668 | -5.938 | -0.023 |
| Income Before Tax Ratio
| 0 | 0 | 1.615 | 0 | 0 | -0.987 | -44.94 | 0 | 0 | 0 | -565.25 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.043 | 0.001 | 6.198 | 5.65 | -0.052 | -0.164 | -0.122 | -0.008 | -0.004 | -0.004 | -4.668 | -5.938 | -0.023 |
| Net Income
| -4.428 | -4.171 | -6.622 | -5.881 | -5.708 | -3.997 | -6.532 | -5.755 | -3.561 | -2.939 | -2.261 | -4.668 | -5.938 | -0.023 |
| Net Income Ratio
| 0 | 0 | 1.615 | 0 | 0 | -0.975 | -43.839 | 0 | 0 | 0 | -565.25 | 0 | 0 | 0 |
| EPS
| -0.26 | -0.25 | -0.38 | -0.37 | -0.38 | -0.27 | -0.45 | -0.41 | -0.28 | -0.32 | -0.18 | -0.39 | -0.47 | -0.002 |
| EPS Diluted
| -0.26 | -0.25 | -0.38 | -0.37 | -0.38 | -0.27 | -0.45 | -0.41 | -0.28 | -0.32 | -0.18 | -0.39 | -0.47 | -0.002 |
| EBITDA
| -4.643 | -4.396 | -6.866 | -6.158 | -5.772 | -4.101 | -6.778 | -5.938 | -3.573 | -2.945 | -2.265 | -4.668 | -5.938 | -0.023 |
| EBITDA Ratio
| 0 | 0 | 1.674 | 0 | 0 | -1 | -45.49 | 0 | 0 | 0 | -566.25 | 0 | 0 | 0 |